Table 2.
The response of the renal tumour to the targeted molecular treatments
| Author | No | Targeted Treatment | Median Size | Median% reduction | <30% regression of size | Partial response | tumour shrinkage (%patients) |
|---|---|---|---|---|---|---|---|
| Thomas,AA [35] | 19 | Sunitinib | 10.5 | 24% | 8 | 3 | 42% |
| Hellenthal NJ [38] | 20 | Sunitinib | 7 | 27.9% | 15 | 2 | 85% |
| Silbertein J [30] | 14 | Sunitinib | 7 | 21% | 10 | 4 | 100% |
| Tsunenon Kondo [39] | 9 | Sunitinib/Sorafenib | – | Range:9–30% | 6 | 3 | 100% |
| Abel [36] | 168 | Multiple Agents | 9.6 | 7.1% | 89 | 10 | 59% |
| Lance Cowey [37] | 30 | Sorafenib | 8.7 | 9.6% | 23 | 2 | 80% |